Xience (everolimus-eluting stent) / Abbott - LARVOL DELTA

Assessment of and Factors Contributing to Adequate Endothelization After Drug-Eluting Stent Implantation. (PubMed, Circ J) - "Functional protection against thrombus requires %ASC ≥67%, and plaque stabilization requires ≥90%. The use of ingenious DESs and prasugrel contributes to improved chronic adequate endothelization."

Journal • Cardiovascular • Hypertension • Thrombosis

Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort. (PubMed, Circ Cardiovasc Interv) - P4 | "The patients after percutaneous coronary intervention with cobalt-chromium everolimus-eluting stents were randomized into 1-month dual antiplatelet therapy followed by clopidogrel monotherapy (clopidogrel group) or 12-month dual antiplatelet therapy followed by aspirin monotherapy (aspirin group). Clopidogrel monotherapy was superior to aspirin monotherapy for cardiovascular outcomes beyond 1 year after percutaneous coronary intervention, without increased bleeding risk. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02619760 and NCT03462498."

Clinical • Journal • Monotherapy • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Chimney stenting for coronary protection in high-risk TAVR patients. (PubMed, Arch Cardiol Mex) - "Balloon-expandable valves and everolimus-eluting stents ≥4.0 mm were deployed...Prophylactic CST appears to be a safe and effective coronary protection strategy during TAVR in patients with high-risk anatomy. Our single-center experience shows favorable long-term outcomes, although additional research is needed to assess very-long-term durability."

Journal

PERCUTANEOUS MANAGEMENT OF GIANT MYCOTIC CORONARY ANEURYSM (ACC 2026) - "We used a 4 x 48 mm Xience DES as a scaffold within which two overlapping covered stents (Papyrus 4 x 20 and 4 x 26 mm) were deployed and successfully sealed off the aneurysmal sac... Mycotic coronary aneurysms are rare complications of bacteremia. Our case highlights successful percutaneous management of a giant mycotic coronary aneurysm."

Cardiovascular • Orthopedics

OVERCOMING CORONARY ANGULATION AND CALCIFICATION WITH A NOVEL FOUR-GENERATION SUPPORT TECHNIQUE (ACC 2026) - "After lesion preparation, a Xience Skypoint drug-eluting stent was delivered without complication... The four-generation support technique is a valuable strategy for surgically ineligible patients with complex and unfavorable anatomy."

Cardiovascular • Myocardial Infarction

BETWEEN A ROCK AND A HARD PLACE: CORONARY EMBOLIZATION OF AORTIC VALVE CALCIUM (ACC 2026) - "We then proceeded to rotational atherectomy and deployment of a 3.5 x 28 mm Xience Skypoint DES... Coronary embolism of aortic valve calcium is a rare but potential risk of coronary angiography in certain patient populations. Management of embolized or entrapped material of any kind requires broad knowledge of all interventional equipment available and creative deployment of multiple strategies. This case also highlights the benefit of cross-specialty collaboration."

Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease

IMPACT OF TOTAL STENT LENGTH ON LONG-TERM OUTCOMES WITH DIFFERENT NEWER-GENERATION DRUG-ELUTING STENT DESIGNS IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A SUBGROUP ANALYSIS FROM THE BIOSTEMI ES RANDOMIZED TRIAL. (PubMed, Am Heart J) - P | "In STEMI patients treated with contemporary DES, TSL >40 mm was associated with an increased risk of patient-oriented, but not device-related, adverse outcomes at 5 years. Among patients requiring TSL >40 mm, ultrathin-strut BP-SES significantly reduced the risk of TLF compared with DP-EES, whereas no between-DES differences were observed in patients treated with TSL ≤40 mm."

Journal • Cardiovascular • Myocardial Infarction

Effectiveness and Safety of Biodegradable Polymer-Coated Everolimus-Eluting Stent in Multivessel Coronary Artery Disease in Routine Clinical Practice: A Korean Multicenter, Prospective, and Observational Study. (PubMed, J Korean Med Sci) - "The 1-year TLF rate observed in our cohort (2.1%) was comparable to or lower than rates previously reported in studies evaluating drug-eluting stents in patients undergoing multivessel PCI. These results suggest that the biodegradable polymer-coated everolimus-eluting stents provide favorable clinical outcomes for this patient population in real-world clinical practice."

Journal • Observational data • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Diabetes • Hematological Disorders • Metabolic Disorders • Myocardial Infarction • Thrombosis

Proximal Anchoring Technique: A Novel Technique to Prevent Coronary Stent Longitudinal Deformation. (PubMed, Rev Cardiovasc Med) - "This bench study was performed in a tapered silicon vessel model, in which 3.5 × 28 mm-sized everolimus-eluting stents (Xience Xpedition™; Abbot, USA) were deployed at a nominal pressure...The OCT measurements showed that the stents were elongated during every step of the procedure in the D-P group (29.35 ± 0.10 mm vs. 29.65 ± 0.10 mm; p = 0.0054), but only slightly elongated in the first step of the post-dilation in the PAT group (28.73 ± 0.12 mm vs. 28.87 ± 0.12 mm; p = 0.2262). We present a novel technique, PAT, to assist in more precise coronary stent implantation by preventing LSD for partial ostial and bifurcation lesions during PCI."

Journal

Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trial. (PubMed, EuroIntervention) - "After complete resorption, no benefit was observed with BVS compared with EES at 7-year follow-up, despite the use of a dedicated implantation protocol for BVS. In fact, after 3 years, more target lesion revascularisations occurred with BVS than with EES."

Clinical • Journal • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Randomized Clinical Trial. (PubMed, JAMA Cardiol) - "To compare the clinical outcomes of ticagrelor vs prasugrel, each in combination with aspirin, in patients with diabetes and multivessel coronary artery disease who underwent percutaneous coronary intervention. The Ultrathin Strut vs Xience in a Diabetic Population With Multivessel Disease 2-India Study (TUXEDO-2) is an investigator-initiated, prospective, open-label, multicenter, 2 × 2 factorial design, 1:1 randomized clinical trial...In patients with diabetes and multivessel disease undergoing PCI, ticagrelor was not noninferior to prasugrel for the reduction of primary outcome at 1 year of follow-up. CTRI/2019/11/022088."

Clinical • Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders • Myocardial Infarction

Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II). (PubMed, J Am Coll Cardiol) - P=N/A | "In IRONMAN-II, the sirolimus-eluting IBS was noninferior to CoCr-EES for 2-year in-segment LLL, QFR, and OCT-derived flow area. Clinical event rates were also comparable between groups although non-ischemia-driven revascularization rates were higher after IBS. Longer-term follow-up is necessary to demonstrate whether late benefits are realized after complete IBS resorption. (A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease; NCT05206084)."

First-in-human • Journal • Cardiovascular • Coronary Artery Disease • Heart Failure • Hematological Disorders • Myocardial Infarction • Myocardial Ischemia • Thrombosis

Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial. (PubMed, Circulation) - "MIs after PCI and CABG for LMCAD were adjudicated from the EXCEL trial (Evaluation of Xience Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization)...In the EXCEL trial, spontaneous MI occurred relatively infrequently within 5 years after LMCAD revascularization but at a higher rate after PCI compared with CABG. Spontaneous MI after revascularization was strongly related to subsequent cardiovascular and all-cause mortality, consistently after PCI and CABG, and was more strongly associated with mortality than was large procedural MI."

Journal • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

COASTLINE: Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents (clinicaltrials.gov) - P=N/A | N=1757 | Completed | Sponsor: Foundation of Cardiovascular Research and Education Enschede | Trial completion date: Apr 2025 ➔ Dec 2025 | Trial primary completion date: Apr 2024 ➔ Dec 2025 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Metabolic Disorders • Myocardial Infarction

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease (clinicaltrials.gov) - P=N/A | N=1629 | Completed | Sponsor: Sino Medical Sciences Technology Inc. | Active, not recruiting ➔ Completed

Trial completion • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease

Comparative effectiveness of percutaneous coronary intervention strategies for coronary small-vessel disease: a network meta-analysis of randomized trials. (PubMed, Ann Med) - "For TLR (37 studies; 11,980 patients), the highest SUCRA values were observed with sirolimus-eluting stents (SES 90.1%), zotarolimus-eluting stents (ZES 83.9%), and everolimus-eluting stents (EES 82.2%). ZES, EES, and DCB-PTX are effective alternatives in selected settings, whereas BMS, POBA, and GPBA are less effective. These findings offer comparative evidence to guide device selection in SVD."

Clinical • HEOR • Journal • Retrospective data • Review • Cardiovascular • Myocardial Infarction

The efficacy of biodegradable polymer everolimus-eluting stents in patients with cardiac allograft vasculopathy. (PubMed, JHLT Open) - "PCI with BP-DES was associated with a lower TVNLR than PCI with DP-DES. Both DES resulted in similar clinical outcomes; however, a long-term investigation is warranted."

Journal • Cardiovascular • Inflammation • Transplantation

EPIC31-PRO-HEAL: Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention. (clinicaltrials.gov) - P=N/A | N=40 | Active, not recruiting | Sponsor: Fundación EPIC | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2026 ➔ May 2026 | Trial primary completion date: Jan 2026 ➔ Apr 2026

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial. (PubMed, Lancet) - P=N/A | "In patients with diabetes undergoing PCI, the Abluminus DES+ SES was not non-inferior to the XIENCE EES, resulting in higher rates of ischaemia-driven target-lesion revascularisation and target lesion failure at 12-month follow-up. Event rates between 12 and 24 months were similar between groups. These findings highlight the persistent challenge of optimising outcomes in patients with diabetes and underscore the need for continued innovation in stent design and adjunctive pharmacotherapy to reduce residual ischaemic risk in this population."

Journal • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Effect of percutaneous coronary intervention for chronic total occlusion on diastolic atrioventricular coupling in ST-elevation myocardial infarction patients. (PubMed, Int J Cardiol) - "Baseline LACI ≥20.6% was associated with an increased risk of all-cause death compared to LACI <20.6% after multivariable adjustment (hazard ratio 2.37, 95% CI: 1.27 to 4.45, P = 0.007) Among STEMI patients with a concurrent CTO, CTO PCI did not affect LACI at 4 months or its improvement over time. Elevated LACI early after STEMI independently predicted long-term all-cause mortality Clinical trial registration: The Evaluating Xience and left ventricular function in PCI on occlusiOns afteR STEMI (EXPLORE) trial; NTR1108 www.trialregister.nl, Date registered NTR: 30-okt-2007."

Journal • Cardiovascular • Myocardial Infarction

Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial) (clinicaltrials.gov) - P=N/A | N=300 | Active, not recruiting | Sponsor: Carelon Research | Trial completion date: Apr 2027 ➔ Feb 2028 | Trial primary completion date: Sep 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure

DestinACSion: Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions (clinicaltrials.gov) - P=N/A | N=2100 | Recruiting | Sponsor: Fundación EPIC | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease

IRIS Skypoint: Evaluation of Effectiveness and Safety of Xience Skypoint Stents in Routine Clinical Practice (clinicaltrials.gov) - P=N/A | N=2000 | Recruiting | Sponsor: Seung-Jung Park | Trial completion date: Feb 2026 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

TRANSFORM II: Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels (clinicaltrials.gov) - P=N/A | N=1820 | Active, not recruiting | Sponsor: Fondazione Ricerca e Innovazione Cardiovascolare ETS | Trial primary completion date: Nov 2025 ➔ Aug 2026 | Trial completion date: Nov 2028 ➔ Aug 2030

Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

IRIS XPEDITION: XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice (clinicaltrials.gov) - P=N/A | N=4000 | Completed | Sponsor: Seung-Jung Park | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Coronary Artery Disease